The reason why it improves anemia is probably because that the half-life of ESAs is longer than of ruxolitinib’s, and JAK2 is maybe not completely inhibited by therapeutic concentrations of ruxolitinib. This evidence concerns the gene JAK2 and anemia (phenotype).